관상동맥 질환 치료 기기 시장 : 디바이스 유형, 재질 구성, 치료법, 접근, 최종 사용자별 예측(2026-2032년)

The Coronary Artery Disease Treatment Devices Market is projected to grow by USD 7.26 billion at a CAGR of 5.94% by 2032.

Coronary artery disease treatment devices are central to modern cardiovascular care, spanning drug-eluting stents, bare-metal stents, balloon catheters, atherectomy systems, thrombectomy devices, intravascular imaging platforms, pressure guidewires, embolic protection devices, and adjunctive technologies used in percutaneous coronary intervention and surgical revascularization.

Demand is anchored by the global burden of ischemic heart disease, which remains the world's leading cause of death according to the World Health Organization. Aging populations, diabetes, obesity, hypertension, tobacco exposure, and improved access to catheterization laboratories continue to sustain procedural volumes, while clinical guidelines increasingly emphasize evidence-based lesion assessment, optimal medical therapy, and patient-specific revascularization strategies.

Transformative Shifts in the Coronary Device Landscape

The coronary artery disease treatment devices landscape is shifting from purely mechanical vessel opening toward precision revascularization. New-generation drug-eluting stents with thinner struts, biocompatible polymers, and improved deliverability have reduced restenosis and stent thrombosis compared with earlier platforms, while drug-coated balloons are expanding options for in-stent restenosis and small-vessel disease in selected patients.

Hospitals and cardiology networks are also adopting intravascular ultrasound, optical coherence tomography, and fractional flow reserve or non-hyperemic pressure ratio tools to improve lesion selection and stent optimization. At the same time, value-based purchasing, same-day discharge pathways after PCI, and growing use of radial access are reshaping procurement priorities toward safety, workflow efficiency, and total cost of care.

Cumulative Impact of Artificial Intelligence on CAD Devices

Artificial intelligence is becoming a cumulative force across coronary artery disease treatment, beginning with risk stratification and extending into imaging, cath lab planning, procedural support, and post-procedure monitoring. AI-enabled analysis of coronary CT angiography, angiograms, IVUS, and OCT can help quantify plaque burden, identify high-risk anatomy, and support more consistent interpretation across operators.

In device markets, AI is also improving operational performance through predictive maintenance, inventory optimization, clinical trial enrichment, and real-world evidence generation. The strongest near-term impact is expected where AI augments clinician decision-making without replacing established guideline-based practice, particularly in lesion assessment, stent sizing, restenosis prediction, and longitudinal follow-up of high-risk patients.

Key Regional Insights for CAD Treatment Devices

Asia-Pacific is a high-growth region for coronary artery disease treatment devices due to large patient pools, rapid hospital infrastructure expansion, and rising adoption of PCI in China, India, Japan, South Korea, and Australia. North America remains a technology leadership hub, supported by advanced cath lab capacity, structured reimbursement, FDA-regulated innovation pathways, and high use of intravascular imaging and physiology-guided intervention.

Europe benefits from mature cardiovascular care networks and guideline-driven adoption of drug-eluting stents, drug-coated balloons, and imaging-guided PCI, with Germany, France, Italy, Spain, and the United Kingdom shaping procedural standards. Latin America is expanding access through private hospital investment and public procurement, led by Brazil and Mexico. The Middle East is investing in tertiary cardiac centers, particularly in GCC markets with high cardiometabolic risk, while Africa shows long-term potential as catheterization infrastructure, specialist training, and device availability improve.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining importance as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore improve access to interventional cardiology, cardiovascular screening, and tertiary hospital services. The GCC is characterized by high cardiometabolic risk, strong hospital investment, and preference for premium cardiovascular technologies in major urban centers, reinforcing demand for advanced stents, imaging systems, and complex PCI support devices.

The European Union supports device adoption through harmonized regulatory oversight under the Medical Device Regulation, although clinical evidence and post-market surveillance requirements have increased market entry complexity. BRICS countries combine large ischemic heart disease burden with expanding domestic manufacturing, procurement localization, and broader cath lab capacity. G7 nations remain key innovation, reimbursement, and clinical evidence markets, while NATO-aligned healthcare systems are creating demand for resilient medical supply chains, cybersecurity-ready digital platforms, and diversified sourcing for critical cardiovascular devices.

Key Country Insights for Coronary Artery Disease Treatment Devices

The United States leads in high-value coronary device utilization, supported by large PCI volumes, advanced imaging use, radial access adoption, and active clinical research. Canada emphasizes quality outcomes and public reimbursement discipline, while Mexico and Brazil are expanding interventional access through mixed public-private systems and growing tertiary care capacity. The United Kingdom, Germany, France, Italy, and Spain continue to influence European practice through guideline implementation, national procurement, structured registries, and strong cardiology societies.

Russia maintains demand through centralized hospital networks but faces procurement and supply-chain complexity. China is scaling domestic stent and catheter production while expanding advanced PCI capacity and hospital access. India combines high disease burden with price-sensitive procurement and rapid cath lab growth. Japan and South Korea are advanced technology adopters with strong operator expertise, high procedural quality expectations, and established use of intravascular imaging, while Australia maintains a mature, outcomes-focused cardiovascular device environment supported by evidence-based reimbursement and specialist cardiac networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence, including randomized trials, registry data, and real-world outcomes for complex PCI, diabetes, small-vessel disease, calcified lesions, bifurcation lesions, and high bleeding-risk patients. Evidence generation should be paired with health-economic models that demonstrate reductions in repeat revascularization, hospital stay, complications, and long-term care costs.

Manufacturers should invest in AI-enabled imaging partnerships, physician training, supply-chain resilience, cybersecurity readiness, and region-specific pricing strategies. Winning portfolios will integrate stents, balloons, atherectomy, thrombectomy, imaging, physiology, and digital workflow tools into procedure-ready solutions that help hospitals improve outcomes while managing reimbursement pressure and procurement scrutiny.

Research Methodology for Market and Clinical Insights

This executive summary is based on triangulation of verified secondary research, clinical guideline review, regulatory intelligence, public health data, peer-reviewed literature, epidemiology databases, and procedure trend analysis. Core references include global cardiovascular disease data from public health authorities, cardiology society recommendations, medical device regulatory frameworks, and published evidence on PCI technologies.

The methodology emphasizes cross-validation across disease burden, technology adoption, reimbursement conditions, regulatory requirements, and regional healthcare capacity. Insights were structured to support strategic planning for coronary artery disease treatment device manufacturers, distributors, investors, hospital procurement teams, and innovation partners operating across developed and emerging cardiovascular markets.

Conclusion: Strategic Outlook for CAD Treatment Devices

The coronary artery disease treatment devices landscape is advancing toward precision, evidence-based, and digitally supported revascularization. Momentum is supported by persistent ischemic heart disease burden, rising procedural access, and continuous innovation across stents, balloons, atherectomy, thrombectomy, imaging, and physiology-guided tools.

Future leadership will depend on clinical differentiation, affordability, regulatory readiness, supply-chain resilience, and integration with AI-enabled decision support. Organizations that align innovation with measurable patient outcomes, cath lab efficiency, and regional access needs will be best positioned to compete in the evolving global CAD treatment ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Coronary Artery Disease Treatment Devices Market, by Device Type

• 7.1. Atherectomy Device
  • 7.1.1. Laser Atherectomy
  • 7.1.2. Orbital Atherectomy
  • 7.1.3. Rotational Atherectomy
• 7.2. Balloon Catheter
  • 7.2.1. Cutting Balloon Catheter
  • 7.2.2. Drug-Coated Balloon Catheter
  • 7.2.3. Standard Balloon Catheter
• 7.3. Intravascular Imaging System
  • 7.3.1. Fractional Flow Reserve
  • 7.3.2. Intravascular Ultrasound
  • 7.3.3. Optical Coherence Tomography
• 7.4. Stent Systems
  • 7.4.1. Bare Metal Stent
  • 7.4.2. Drug Eluting Stent

8. Coronary Artery Disease Treatment Devices Market, by Material Composition

• 8.1. Metals
  • 8.1.1. Stainless Steel
  • 8.1.2. Cobalt-Chromium
  • 8.1.3. Platinum-Chromium
• 8.2. Polymers
• 8.3. Bioabsorbable
  • 8.3.1. Magnesium Alloys
  • 8.3.2. Poly-L-lactic Acid

9. Coronary Artery Disease Treatment Devices Market, by Treatment Type

• 9.1. Coronary Artery Bypass Grafting
  • 9.1.1. Off Pump
  • 9.1.2. On Pump
• 9.2. Percutaneous Coronary Intervention

10. Coronary Artery Disease Treatment Devices Market, by Approach

• 10.1. Transfemoral Approach
• 10.2. Transradial Approach

11. Coronary Artery Disease Treatment Devices Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Cardiac Centers
• 11.3. Hospitals & Clinics

12. Coronary Artery Disease Treatment Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Coronary Artery Disease Treatment Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Coronary Artery Disease Treatment Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Abiomed, Inc.
• 16.3. AngioDynamics, Inc.
• 16.4. B. Braun Melsungen AG
• 16.5. Becton, Dickinson and Company
• 16.6. Biosensors International Group, Ltd.
• 16.7. Biotronik SE & Co. KG
• 16.8. Boston Scientific Corporation
• 16.9. Cardinal Health, Inc.
• 16.10. Cook Medical Inc.
• 16.11. Edwards Lifesciences Corporation
• 16.12. Johnson & Johnson Services Inc.
• 16.13. Koninklijke Philips N.V.
• 16.14. Lepu Medical Technology (Beijing) Co., Ltd.
• 16.15. Medtronic plc
• 16.16. Meril Life Sciences Pvt. Ltd.
• 16.17. Merit Medical Systems, Inc.
• 16.18. MicroPort Scientific Corporation
• 16.19. Penumbra, Inc.
• 16.20. Shockwave Medical, Inc.
• 16.21. Teleflex Incorporated
• 16.22. Terumo Corporation
• 16.23. W. L. Gore & Associates, Inc.
• 16.24. Zylox-Tonbridge Medical Technology Co., Ltd.